 Douglas Ney
Concepts (141)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 17 | 2021 | 1164 | 1.900 |
Why?
| | Central Nervous System Neoplasms | 4 | 2023 | 148 | 1.270 |
Why?
| | Glioblastoma | 8 | 2019 | 322 | 0.950 |
Why?
| | Neurology | 3 | 2019 | 104 | 0.800 |
Why?
| | Mycosis Fungoides | 2 | 2018 | 62 | 0.700 |
Why?
| | Lymphoma | 3 | 2023 | 194 | 0.680 |
Why?
| | Quality Improvement | 2 | 2018 | 1099 | 0.660 |
Why?
| | Radiotherapy, Intensity-Modulated | 3 | 2015 | 128 | 0.640 |
Why?
| | Oligodendroglioma | 3 | 2021 | 15 | 0.630 |
Why?
| | Chemoradiotherapy | 3 | 2015 | 209 | 0.620 |
Why?
| | Health Services | 1 | 2018 | 103 | 0.550 |
Why?
| | Dacarbazine | 5 | 2016 | 97 | 0.470 |
Why?
| | Quality of Health Care | 1 | 2018 | 608 | 0.420 |
Why?
| | Skin Neoplasms | 2 | 2018 | 833 | 0.420 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2023 | 1573 | 0.390 |
Why?
| | Delivery of Health Care | 1 | 2018 | 894 | 0.350 |
Why?
| | Cerebral Ventricle Neoplasms | 1 | 2010 | 4 | 0.340 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2010 | 76 | 0.330 |
Why?
| | Antineoplastic Agents, Alkylating | 3 | 2016 | 69 | 0.330 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2010 | 71 | 0.330 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 87 | 0.320 |
Why?
| | Meningioma | 1 | 2010 | 81 | 0.310 |
Why?
| | Meningeal Neoplasms | 1 | 2010 | 93 | 0.310 |
Why?
| | Astrocytoma | 2 | 2021 | 121 | 0.290 |
Why?
| | Medical Oncology | 2 | 2021 | 274 | 0.280 |
Why?
| | Lymphoproliferative Disorders | 1 | 2023 | 54 | 0.200 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2023 | 92 | 0.190 |
Why?
| | Hashimoto Disease | 1 | 2020 | 11 | 0.170 |
Why?
| | Survival Rate | 3 | 2015 | 1875 | 0.170 |
Why?
| | Meningoencephalitis | 1 | 2020 | 25 | 0.170 |
Why?
| | Fatal Outcome | 2 | 2018 | 301 | 0.170 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2020 | 93 | 0.170 |
Why?
| | Aged | 13 | 2023 | 22083 | 0.160 |
Why?
| | Bevacizumab | 3 | 2015 | 131 | 0.160 |
Why?
| | Middle Aged | 14 | 2023 | 31074 | 0.160 |
Why?
| | Oncologists | 1 | 2019 | 37 | 0.160 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2015 | 376 | 0.160 |
Why?
| | Humans | 25 | 2023 | 129116 | 0.160 |
Why?
| | Neurologic Examination | 1 | 2019 | 115 | 0.150 |
Why?
| | Encephalitis | 1 | 2020 | 132 | 0.150 |
Why?
| | Hospice and Palliative Care Nursing | 1 | 2019 | 75 | 0.150 |
Why?
| | Patient Care | 1 | 2018 | 110 | 0.140 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2012 | 508 | 0.130 |
Why?
| | Alzheimer Disease | 1 | 2022 | 518 | 0.130 |
Why?
| | Follow-Up Studies | 4 | 2015 | 4915 | 0.130 |
Why?
| | Male | 15 | 2020 | 63194 | 0.130 |
Why?
| | Neurosurgical Procedures | 1 | 2017 | 172 | 0.130 |
Why?
| | Rituximab | 2 | 2023 | 163 | 0.120 |
Why?
| | Prognosis | 3 | 2015 | 3788 | 0.120 |
Why?
| | Radiotherapy | 1 | 2016 | 185 | 0.120 |
Why?
| | Combined Modality Therapy | 3 | 2016 | 1209 | 0.120 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 439 | 0.120 |
Why?
| | Neoplasm Staging | 2 | 2015 | 1293 | 0.110 |
Why?
| | Seizures | 1 | 2017 | 399 | 0.110 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2014 | 211 | 0.110 |
Why?
| | Societies, Medical | 1 | 2018 | 749 | 0.110 |
Why?
| | Eosinophilia | 1 | 2015 | 205 | 0.100 |
Why?
| | Adult | 10 | 2017 | 35510 | 0.100 |
Why?
| | Curriculum | 1 | 2019 | 925 | 0.100 |
Why?
| | Isocitrate Dehydrogenase | 1 | 2012 | 51 | 0.100 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2739 | 0.090 |
Why?
| | Prospective Studies | 4 | 2015 | 7079 | 0.090 |
Why?
| | Disease Progression | 3 | 2019 | 2613 | 0.080 |
Why?
| | Female | 12 | 2019 | 68510 | 0.080 |
Why?
| | Treatment Outcome | 5 | 2021 | 10226 | 0.080 |
Why?
| | Mutation | 2 | 2012 | 3700 | 0.080 |
Why?
| | Receptors, Platelet-Derived Growth Factor | 1 | 2009 | 14 | 0.080 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 2009 | 23 | 0.080 |
Why?
| | Internship and Residency | 1 | 2019 | 1061 | 0.080 |
Why?
| | Disease-Free Survival | 1 | 2010 | 656 | 0.080 |
Why?
| | Genes, p53 | 1 | 2009 | 70 | 0.080 |
Why?
| | Remission Induction | 1 | 2009 | 271 | 0.080 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2009 | 89 | 0.080 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2009 | 70 | 0.080 |
Why?
| | Chromosome Deletion | 1 | 2009 | 102 | 0.080 |
Why?
| | Aged, 80 and over | 3 | 2023 | 7064 | 0.080 |
Why?
| | Angiogenesis Inhibitors | 1 | 2009 | 216 | 0.070 |
Why?
| | Chromosome Mapping | 1 | 2009 | 505 | 0.070 |
Why?
| | Ependymoma | 1 | 2009 | 176 | 0.070 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2012 | 963 | 0.070 |
Why?
| | Age Factors | 2 | 2014 | 3120 | 0.070 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 280 | 0.070 |
Why?
| | Multiple Sclerosis | 1 | 2012 | 437 | 0.070 |
Why?
| | Retrospective Studies | 6 | 2023 | 14571 | 0.070 |
Why?
| | Recurrence | 1 | 2009 | 1003 | 0.060 |
Why?
| | Alleles | 1 | 2009 | 845 | 0.060 |
Why?
| | Postoperative Complications | 1 | 2017 | 2496 | 0.060 |
Why?
| | Diagnosis, Differential | 1 | 2010 | 1417 | 0.060 |
Why?
| | ErbB Receptors | 1 | 2009 | 603 | 0.060 |
Why?
| | Immunotherapy | 1 | 2009 | 588 | 0.060 |
Why?
| | DNA Methylation | 1 | 2009 | 605 | 0.050 |
Why?
| | Cytarabine | 1 | 2023 | 56 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 2009 | 1359 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2023 | 151 | 0.050 |
Why?
| | Methotrexate | 1 | 2023 | 250 | 0.050 |
Why?
| | Quality of Life | 1 | 2013 | 2693 | 0.050 |
Why?
| | Central Nervous System | 1 | 2023 | 255 | 0.040 |
Why?
| | Activities of Daily Living | 1 | 2023 | 389 | 0.040 |
Why?
| | Hope | 1 | 2019 | 22 | 0.040 |
Why?
| | Clinical Decision-Making | 1 | 2021 | 305 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2023 | 690 | 0.040 |
Why?
| | Consensus | 1 | 2021 | 638 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2009 | 2060 | 0.040 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 174 | 0.040 |
Why?
| | Evidence-Based Medicine | 1 | 2021 | 718 | 0.040 |
Why?
| | Neuroimaging | 1 | 2019 | 277 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2021 | 1943 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 2017 | 132 | 0.030 |
Why?
| | Incidence | 1 | 2023 | 2635 | 0.030 |
Why?
| | Time Factors | 2 | 2021 | 6518 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1363 | 0.030 |
Why?
| | Anticonvulsants | 1 | 2017 | 198 | 0.030 |
Why?
| | Child, Preschool | 1 | 2010 | 10450 | 0.030 |
Why?
| | Marital Status | 1 | 2014 | 45 | 0.030 |
Why?
| | SEER Program | 1 | 2014 | 206 | 0.030 |
Why?
| | Biopsy | 1 | 2017 | 1086 | 0.030 |
Why?
| | Karnofsky Performance Status | 1 | 2013 | 38 | 0.030 |
Why?
| | Palliative Care | 1 | 2019 | 721 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2014 | 1271 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2012 | 386 | 0.020 |
Why?
| | Tumor Burden | 1 | 2012 | 283 | 0.020 |
Why?
| | Biomarkers | 1 | 2022 | 3896 | 0.020 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 157 | 0.020 |
Why?
| | Databases, Factual | 1 | 2016 | 1279 | 0.020 |
Why?
| | Dexamethasone | 1 | 2012 | 340 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2017 | 3342 | 0.020 |
Why?
| | Reoperation | 1 | 2012 | 560 | 0.020 |
Why?
| | Sex Factors | 1 | 2014 | 1953 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2013 | 1004 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 471 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3260 | 0.020 |
Why?
| | Young Adult | 2 | 2017 | 12389 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2009 | 864 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2009 | 1013 | 0.020 |
Why?
| | Cohort Studies | 1 | 2016 | 5407 | 0.020 |
Why?
| | Adolescent | 2 | 2017 | 20301 | 0.020 |
Why?
| | Cognition | 1 | 2013 | 1111 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2009 | 764 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2267 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2012 | 3383 | 0.010 |
Why?
| | United States | 1 | 2014 | 13938 | 0.010 |
Why?
|
|
Ney's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|